SCHEMBL698061

SCHEMBL698061

CS(=O)(=O)NC(Cc1ccccc1)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 9/20 0.63
MMP9 P14780 7/20 0.63
ADAMTS4 O75173 1/20 0.63
ALDH1A1 P00352 1/20 0.59
MAPT P10636 1/20 0.59
POLB P06746 1/20 0.59
ITGB3 P05106 2/20 0.58
ITGA2B P08514 1/20 0.58
ADAMTS5 Q9UNA0 1/20 0.56
MMP1 P03956 1/20 0.56
MMP3 P08254 1/20 0.56
MMP7 P09237 1/20 0.56
MMP13 P45452 1/20 0.56
HTT P42858 1/20 0.56
ITGAV P06756 1/20 0.53
PPARG P37231 1/20 0.52
MME P08473 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6436714 1.00 MMP2 (0.63) MMP2MMP9ADAMTS4ALDH1A1MAPT
SCHEMBL698062 1.00 MMP2 (0.63) MMP2MMP9ADAMTS4ALDH1A1MAPT
Benzene SCHEMBL28198278 1.00 MMP2 (0.63) MMP2MMP9ADAMTS4ALDH1A1MAPT
SCHEMBL27445164 0.94 MMP2 (0.57) MMP2MMP9ADAMTS4ALDH1A1MAPT
D-Phenylalanine SCHEMBL8609785 0.91 ALPI (0.63) MMP2MMP9ADAMTS4ALDH1A1MAPT
SCHEMBL9012465 0.89 MME (0.60) MMP2MMP9ADAMTS4MME
SCHEMBL16473194 0.88 MMP2 (0.50) MMP2MMP9ADAMTS4ALDH1A1MAPT
SCHEMBL16886887 0.87 CYP3A4 (0.57) MMP2MMP9ADAMTS4ALDH1A1MAPT
SCHEMBL16886884 0.87 CYP3A4 (0.57) MMP2MMP9ADAMTS4ALDH1A1MAPT
SCHEMBL11471487 0.87 POLB (0.49) MMP2MMP9ADAMTS4ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117337176-A C5AR1 inhibitors for treating hypersensitivity to taxanes 东佩制药股份公司 2024-01-02 CN claimed
CN-106947792-A The preparation method of one inter-species methylsulfonyl L phenylalanines 上海倍殊生物科技有限公司 2017-07-14 CN claimed
CN-117337176-A C5AR1 inhibitors for treating hypersensitivity to taxanes 东佩制药股份公司 2024-01-02 CN disclosed
EP-3980048-A2 PEPTIDE INHIBITORS FOR THE INHIBITION OF HIV CAPSID The Curators Of The University Of Missouri (US) 2022-04-13 EP disclosed
EP-3342599-B1 HEAT-SENSITIVE RECORDING MATERIAL SANKO CO LTD (JP) 2021-06-16 EP disclosed
WO-2020247933-A2 PEPTIDE INHIBITORS FOR THE INHIBITION OF HIV CAPSID THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) 2020-12-10 WO disclosed
CN-108025574-B Thermal recording medium 三光株式会社 2019-04-16 CN disclosed
US-10086634-B2 Heat-sensitive recording material SANKO CO., LTD. (JP) 2018-10-02 US disclosed
US-20180194151-A1 HEAT-SENSITIVE RECORDING MATERIAL SANKO CO., LTD. (JP) 2018-07-12 US disclosed
EP-3342599-A1 HEAT-SENSITIVE RECORDING MATERIAL Sanko Co., Ltd. (JP) 2018-07-04 EP disclosed
CN-108025574-A Thermal recording medium 三光株式会社 2018-05-11 CN disclosed
EP-2423211-A1 PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF Kaneka Corporation (JP) 2012-02-29 EP disclosed
EP-1505062-A1 Heterocyclic derivatives and their use as antithrombotic agents Akzo Nobel N.V. (NL) 2005-02-09 EP disclosed
US-6797710-B2 CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY AKZO NOBEL N.V. (NL) 2004-09-28 US disclosed
US-20030130270-A1 Heterocyclic derivatives and their use as antithrombotic agents MERCK SHARP & DOHME B.V. (NL) 2003-07-10 US disclosed
US-6444672-B1 ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR AKZO NOBEL N.V. (NL) 2002-09-03 US disclosed
US-6432955-B1 ANTICOAGULANTS AKZO NOBEL N.V. (NL) 2002-08-13 US disclosed
US-6194409-B1 SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH AKZO NOBEL N.V. (NL) 2001-02-27 US disclosed
EP-0975600-A1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS Akzo Nobel N.V. (NL) 2000-02-02 EP disclosed
WO-1998047876-A1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS AKZO NOBEL N.V. (NL) 1998-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180194151-A1 HEAT-SENSITIVE RECORDING MATERIAL ASIC1, SCN1A, NPR1 MMP2 3267/4885MMP9 3602/4885ADAMTS4 4559/4885
US-10086634-B2 Heat-sensitive recording material ASIC1, SCN1A, NPR1 MMP2 3320/4885MMP9 3339/4885ADAMTS4 4570/4885
US-20030130270-A1 Heterocyclic derivatives and their use as antithrombotic agents F2, F12, VKORC1 MMP2 879/4885MMP9 477/4885ADAMTS4 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.